ESTRO 2024 - Abstract Book

S2469

Clinical - Urology

ESTRO 2024

OTT has a meaningful impact on PROs. The results did not demonstrate any differences in high grade toxicity, with only one grade 3+ toxicity recorded by 24 months.

Keywords: SBRT, MR-Linac, Over all treatment time

References:

1. Jackson WC, Silva J, Hartman HE, et al: Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol Biol Phys 104:778-789, 2019 2. Nicholas van As AT, Jaymini Patel, Peter Ostler, Hans van der Voet, Andrew Loblaw, William Chu, Daniel Ford, Shaun, Tolan SJ, John G Armstrong, Philip Camilleri, Kiran Kancherla, John Frew, Andrew Chan, Olivia Naismith, Georgina, Manning SB, Clare Griffin, Emma Hall: 5-year outcomes from PACE-B: An international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) vs conventionally fractionated or moderately hypofractionated external beam radiotherapy for localised prostate cancer, American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting, 2023 3. Tree AC, Ostler P, van der Voet H, et al: Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non inferiority trial. Lancet Oncol 23:1308-1320, 2022 Widmark A, Gunnlaugsson A, Beckman L, et al: Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394:385-395, 2019 4. 6. Wegener D, Thome A, Paulsen F, et al: First Experience and Prospective Evaluation on Feasibility and Acute Toxicity of Online Adaptive Radiotherapy of the Prostate Bed as Salvage Treatment in Patients with Biochemically Recurrent Prostate Cancer on a 1.5T MR-Linac. J Clin Med 11, 2022 de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, et al: The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Front Oncol 10:1328, 2020 Teunissen FR, Willigenburg T, Tree AC, et al: Magnetic Resonance-Guided Adaptive Radiation therapy for Prostate Cancer: The First Results from the MOMENTUM study-An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy. Pract Radiat Oncol, 2022 Teunissen FR, Willigenburg T, Tree AC, et al: Magnetic Resonance-Guided Adaptive Radiation Therapy for Prostate Cancer: The First Results from the MOMENTUM study-An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy. Pract Radiat Oncol 13:e261-e269, 2023 7. 8. 9. 5. Winkel D, Bol GH, Kroon PS, et al: Adaptive radiotherapy: The Elekta Unity MR-linac concept. Clin Transl Radiat Oncol 18:54-59, 2019

10.

https://prostatecanceruk.org/prostate-information/about-prostate-cancer,